The Versatility of Adhesion Receptor Ligands in Haemostasis: Morpho-Regulatory Functions of Vitronectin

• References

• 1 Preissner KT, de Groot PG. Platelet adhesion molecules in natural immunity. In The Natural Immune System Humoral Factors. Sim E, Kerr MA. (eds) Oxford University Press; Oxford: 1993. pp 281-318
• 2 Lin CQ, Bissell MJ. Multi-faceted regulation of cell differentiation by extracellular matrix. FASEB J 1993; 7: 737-743
• 3 Raghow R. The role of extracellular matrix in post-inflammatory wound healing and fibrosis. FASEB J 1994; 8: 823-831
• 4 Benezra M, Vlodavsky I, Ishai-Michaeli R, Neufeld G, Bar Shavit R. Thrombin-induced release of active basic fibroblast growth factor-heparan sulfate complexes from subendothelial extracellular matrix. Blood 1993; 81: 3324-3331
• 5 Saksela O, Rifkin DB. Cell-associated plasminogen activation Regulation and physiological functions. Ann Rev Cell Biol 1988; 4: 93-126
• 6 Sage EH, Bornstein P. Extracellular proteins that modulate cell- matrix interactions spare tenascin and thrombospondin. J Biol Chem 1991; 266: 14831-14834
• 7 Preissner KT. Structure and biological role of vitronectin. Ann Rev Ceil Biol 1991; 7: 275-310
• 8 Iruela-Arispe ML, Bornstein P, Sage H. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci USA 1991; 88: 5026-5030
• 9 Lahav J. The functions of thrombospondin and its involvement in physiology and pathophysiology. Biochim Biophys Acta 1993; 1182: 1-14
• 10 Murphy-Ullrich JE, Schultz-Cherry S, Hook M. Transforming growth factor-/? complexes with thrombospondin. Mol Biol Cell 1992; 3: 181-188
• 11 Lane TF, Sage EH. The biology of SPARC a protein that modulates cell-matrix interactions. FASEB J 1994; 8: 163-173
• 12 Spring I, Beck K, Chiquet-Ehrismann R. Two contrary functions of tenascin Dissection of the active sites by recombinant tenascin fragments. Cell 1989; 59: 325-334
• 13 Sriramarao P, Mendler M, Bourdon MA. Endothelial cell attachment and spreading on human tenascin is mediated by a2j3l and aV/33 integrins. J Cell Sci 1993; 105: 1001-1012
• 14 Chung CY, Erickson HP. Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-c. J Cell Biol 1994; 126: 539-548
• 15 Tomasini BR, Mosher DF. Vitronectin. Prog Hemostas Thromb 1990; 10: 269-305
• 16 Preissner KT, Jenne DVitronectin. a new molecular connection in haemostasis. Thromb Haemostas 1991; 66: 189-194
• 17 Dahlback K, Lofberg H, Dahlback B. Localization of vitronectin (S-protein of complement) in normal human skin. Acta Derm Venereol 1986; 66: 461-467
• 18 Falk RJ, Podack E, Dalmasso AP, Jennette JC. Localization of S protein and its relationship to the membrane attack complex of complement in renal tissue. Am J Pathol 1987; 127: 182-190
• 19 Niculescu F, Rus HG, Vlaicu R. Immunohistochemical localization of C5b-9 S-protein C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis 1987; 65: 1-11
• 20 Reilly JT, Nash JR G. Vitronectin (serum spreading factor) Its localisation in normal and fibrotic tissue. J Clin Pathol 1988; 41: 1269-1272
• 21 Guettier C, Hinglais N, Bruneval P, Kazatchkine M, Bariety J, Camilleri JP. Immunohistochemical localization of S protein/ vitronectin in human atherosclerotic versus arteriosclerotic arteries. Virchows Arch A Pathol Anat 1989; 414: 309-313
• 22 Bariety J, Hinglais N, Bhakdi S, Mandet C, Rouchon M, Kazatchkine MD. Immunohistochemical study of complement S protein (vitronectin) in normal and diseased human kidneys Relationship to neoantigens of the C5b-9 terminal complex. J Clin Exp Immunol 1989; 75: 76-81
• 23 Sato R, Komine Y, Imanaka T, Takano TJ. Monoclonal antibody EMR la/212D recognizing site of deposition of extracellular lipid in atherosclerosis Isolation and characterization of a cDNA clone for the antigen. I Biol Chem 1990; 265: 21232-21236
• 24 Dahlback K, Lofberg H, Alumets J, Dahlback B. Immunohistochemical demonstration of age-related deposition of vitronectin (S-protein of complement) and terminal complement complex on dermal elastic fibers. I Invest Dermatol 1989; 92: 727-733
• 25 Seiffert D, Crain K, Wagner NV, Loskutoff DJ. Vitronectin gene expression in vivo evidence for extrahepatic synthesis and acute phase regulation. J Biol Chem 1994; 269: 19836-19842
• 26 Seiffert D, Poenninger J, Binder BR. Organization of the gene encoding mouse vitronectin. Gene 1993; 134: 303-304
• 27 Lane DA, Flynn AM, Pejler G, Lindahl U, Choay I, Preissner KT. Structural requirements for the neutralization of heparin-like saccharides by complement S protein/vitronectin. J Biol Chem 1987; 262: 16343-16349
• 28 Gebb C, Hayman EG, Engvall E, Ruoslahti E. Interaction of vitronectin with collagen. J Biol Chem 1986; 261: 16698-16703
• 29 Sane DC, Moser TL, Greenberg CS. Vitronectin in the substratum of endothelial cells is cross-linked and phosphorylated. Biochem Biophys Res Commun 1991; 174: 465-469
• 30 Ehrlich HI, Richter B, von der Ahe D, Preissner KT. Primary structure of vitronectins and homology with other proteins. In Biology of Vitronectins and Their Receptors Preissner KT, Rosenblatt S, Wegerhoff J, Kost C, Mosher DF. (eds) Elsevier; Amsterdam: 1993. pp 59-66
• 31 Seiffert D, Ciambrone G, Wagner NV, Binder BR, Loskutoff DJ. The somatomedin B domain of vitronectin Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. I Biol Chem 1994; 269: 2659-2666
• 32 Tomasini-Johansson B, Ruoslahti E, Pierschbacher MD. A 30 kD sulfated extracellular matrix protein immunologically crossreactive with vitronectin. Matrix 1993; 13: 203-214
• 33 Suzuki S, Pierschbacher MD, Hayman EG, Nguyen K, Ohgren Y, Ruoslahti E. Domain structure of vitronectin. J Biol Chem 1984; 259: 15307-15314
• 34 Cherny RC, Honan MA, Thiagarajan P. Site-directed mutagenesis of the arginine-glycine-aspartic acid in vitronectin abolishes cell adhesion. I Biol Chem 1993; 268: 9725-9729
• 35 Cardin AD, Weintraub HJ R. Molecular modeling of protein-glycos- aminoglycan interactions. Arteriosclerosis 1989; 9: 21-31
• 36 Preissner KT, Grulich-Henn J, Ehrlich HI, Declerck P, Justus C, Collen D, Pannekoek H, Miiller-Berghaus G. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J Biol Chem 1990; 265: 18490-18498
• 37 Kost C, Stiiber W, Ehrlich H, Pannekoek H, Preissner KT. Mapping of binding sites for heparin plasminogen activator inhibitor-1 and plasminogen to vitronectin’s heparin binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation. J Biol Chem 1992; 267: 12098-12105
• 38 Izumi M, Yamada KM, Hayashi M. Vitronectin exists in two structurally and functionally distinct forms in human plasma. Biochim Biophys Acta 1989; 990: 101-108
• 39 Preissner KT, Miiller-Berghaus G. Neutralisation and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III Involvement of an inducible heparin binding domain of S protein/vitronectin. J Biol Chem 1987; 262: 12247-12253
• 40 Jenne D, Hide A, Stanley KK, Huttner WB. Sulfation of two tyrosine-residues in human complement S-protein (vitronectin). Eur J Biochem 1989; 185: 391-395
• 41 Stockmann A, Hess S, Declerck P, Timpl R, Preissner KT. Multimeric Vitronectin Identification and characterization of conformation-dependent self-association of the adhesive protein. J Biol Chem 1993; 268: 22874-22882
• 42 Bittorf SV, Williams EC, Mosher DF. Alteration of vitronectin Characterization of changes induced by treatment with urea. J Biol Chem 1993; 268: 24838-24846
• 43 Tomasini BR, Mosher DF, Owen MC, Fenton JW. Conformational lability of vitronectin Induction of an antigenic change by a-throm- bin-serpin complexes and by proteolytically modified thrombin. Biochemistry 1989; 28: 832-842
• 44 Hogasen K, Mollnes TE, Harboe M. Heparin-binding properties of vitronectin are linked to complex formation as illustrated by in vitro polymerization and binding to the terminal complement complex. J Biol Chem 1992; 267: 23076-23082
• 45 Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1991; 88: 11555-11558
• 46 Korc-Grodzicki B, Tauber-Finkelstein M, Chain D, Shaltiel S. Vitronectin is phosphorylated by a cAMP-dependent protein kinase released by activation of human platelets with thrombin. Biochem Biophys Res Commun 1988; 157: 1131-1138
• 47 Podack ER, Miiller-Eberhard HJ. Isolation of human S-protein an inhibitor of the membrane attack complex of complement. J Biol Chem 1979; 254: 9908-9914
• 48 Ill CR, Ruoslahti E. Association of thrombin-antithrombin III complex with vitronectin in serum. J Biol Chem 1985; 260: 15610-15615
• 49 Preissner KT, Zwicker L, Miiller-Berghaus G. Formation characterization and detection of a ternary complex between S protein thrombin and antithrombin III in serum. Biochem J 1987; 243: 105-111
• 50 de Boer HC, de Groot PG, Bouma BN, Preissner KT. Ternary vitronectin-thrombin-antithrombin III complexes in human plasma detection and mode of association. J Biol Chem 1993; 268: 1279-1283
• 51 Preissner kT, de Boer H, Pannekoek H, de Groot PG. Thrombin regulation by physiological inhibitors the role of vitronectin. Semin Thromb Haemostas. 1995 in press
• 52 Yatohgo T, Izumi M, Kashiwagi H, Hayashi M. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct Funct 1988; 13: 281-292
• 53 Izumi M, Shimo-Oka T, Morishita N, Ii I, Hayashi M. Identification of the collagen-binding domain of vitronectin using monoclonal antibodies. Cell Struct Funct 1988; 13: 217-225
• 54 Rosenblatt S, Timpl R, Preissner KT. Specific binding of vitronectin to components of the extracellular matrix. Ann Hematol 1993; 66 Suppl (Suppl. 01) A44
• 55 Hess S, Stockmann A, Volker W, Preissner KT. Multimeric vitronectin structure and function. In Biology of Vitronectins and Their Receptors Preissner KT, Rosenblatt S, Wegerhoff J, Kost C, Mosher DF. (eds) Elsevier; Amsterdam: 1993. pp 21-30
• 56 Preissner KT, Kost C, Rosenblatt S, de Boer H, Hammes HP, Pannekoek H. The role of fibrinolysis in the cross-talks among vessel wall components the vitronectin-PAI-1 axis. Fibrinolysis 1993; 7 Suppl (Suppl. 01) 18-19
• 57 Yost JC, Sage EH. Specific interaction of SPARC with endothelial cells is mediated through a carboxyl-terminal sequence containing a calcium-binding EF hand. J Biol Chem 1993; 268: 25790-25796
• 58 Naito M, Hayashi T, Funaki C, Kuzuya M, Asai K, Yamada K, Kuzuya F. Vitronectin-induced haptotaxis of vascular smooth muscle cells in vitro. Exp Cell Res 1991; 194: 154-156
• 59 Ciambrone GJ, McKeown-Longo PJ. Plasminogen activator inhibitor type I stabilizes vitronectin-dependent adhesions in HT-1080 cells. I Cell Biol 1990; 111: 2183-2195
• 60 Mimuro J, Loskutoff DJ. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. I Biol Chem 1989; 264: 5058-5063
• 61 Ehrlich HI, Klein GebbinkR, Preissner KT, Keijer J, Esmon NL, Mertens K, Pannekoek H. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix. J Cell Biol 1991; 115: 1773-1781
• 62 Korner G, Bjomsson TD, Vlodavsky I. Extracellular matrix produced by cultured corneal and aortic endothelial cells contains active tissue-type and urokinase-type plaminogen activators. I Cell Physiol 1993; 154: 456-465
• 63 Preissner KT. Specific binding of plasminogen to vitronectin Evidence for a modulatory role of vitronectin on fibrin(ogen)- induced plasmin formation by tissue plasminogen activator. Biochem Biophys Res Commun 1990; 168: 966-971
• 64 Plow EF, Miles LA. Plasminogen receptors in the mediation of pericellular proteolysis. Cell Differ Dev 1990; 32: 263-276
• 65 Chain D, Kreizman T, Shapira H, Shaltiel S. Plasmin cleavage of vitronectin Identification of the site and consequent attentuation in binding plasminogen activator inhibitor-1. FEBS Lett 1991; 285: 251-256
• 66 Grinnell F, Ho CH, Wysocki A. Degradation of fibronectin and vitronectin in chronic wound fluid Analysis by cell blotting immunoblotting and cell adhesion assays. J Invest Dermatol 1992; 98: 410-416
• 67 Kramer MD, Gissler HM, Weidenthaler-Barth B, Preissner KT. Vitronectin and plasmin(ogen) in lesional skin of the bullous pemphigoid colocalisation suggests binding interactions. In Biology of Vitronectins and Their Receptors Preissner KT, Rosenblatt S, Kost C, Wegerhoff J, Mosher DF. (eds) Elsevier; Amsterdam: 1993. pp 295-301
• 68 Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol 1993; 5: 864-868
• 69 Vogel BE, Lee SJ, Hildebrand A, Craig W, Pierschbacher MD, Wong-Staal F, Ruoslahti E. A novel integrin specificity exemplified by binding of the av(35 integrin to the basic domain of the HIV tat protein and vitronectin. J Cell Biol 1993; 121: 461-468
• 70 Dsouza SE, Haas TA, Piotrowicz RS, Byersward V, Meg rath DE, Soule HR, Cierniewski C, Plow EF, Smith JW. Ligand and cationbinding are dual functions of a discrete segment of the integrin (33 subunit - cation displacement is involved in ligand-binding. Cell 1994; 79: 659-667
• 71 Loftus JC, Smith JW, Ginsberg MH. Integrin-mediated cell adhesion - the extracellular face. J Biol Chem 1994; 269: 25235-25238
• 72 Conforti G, Zanetti A, Pasquali-Ronchetti I, Quadlino Jr D, Neyroz P, Dejana E. Modulation of vitronectin receptor binding by membrane lipid composition. J Biol Chem 1990; 265: 4011-4019
• 73 Orlando RA, Cheresh DA. Arginine-glycine-aspartic acid binding leading to molecular stabilization between integrin αv-β3 and its ligand. J Biol Chem 1991; 266: 19543-19550
• 74 Conforti G, Calza M, Beltran-Nunez A. αvβ5 integrin is localized at focal contacts by HT-1080 fibrosarcoma cells and human skin fibroblasts attached to vitronectin. Cell Adhes Comm 1994; 1: 279-293
• 75 Klemke RL, Yebra M, Bayna EM, Cheresh DA. Receptor tyrosine kinase signaling required for integrin αvβ5-directed cell motility but not adhesion on vitronectin. J Cell Biol 1994; 127: 859-866
• 76 Kim JP, Zhang K, Chen JD, Kramer RH, Woodley DT. Vitronectin-driven human keratinocyte locomotion is mediated by the αvβ5 integrin reeptor. J Biol Chem 1994; 269: 26926-26932
• 77 Brown SL, Lundgren CH, Nordt T, Fujii S. Stimulation of migration of human aortic smooth muscle cells by vitronectin implications for atherosclerosis. Cardiovasc Res 1994; 28: 1815-1820
• 78 Leavesley DI, Schwartz MA, Rosenfeld M, Cheresh DA. Integrin β1- and β3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J Cell Biol 1992; 121: 163-170
• 79 Hendey B, Klee CB, Maxfield FR. Inhibition of neutrophil chemoki- nesis on vitronectin by inhibitors of calcineurin. Science 1992; 258: 296-299
• 80 Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteo- pontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 1994; 74: 214-224
• 81 Schaller MD, Borgman CA, Cobb BC, Reynolds AB, Parsons JT. ppl25FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA 1992; 89: 5192-5196
• 82 Zachary I, Rozengurt E. Focal adhesion kinase (pl25FAK) a point of convergence in the action of neuropeptides integrins and oncogenes. Cell 1992; 71: 891-894
• 83 Bauer JS, Schreiner CL, Giancotti FG, Ruoslahti E, Juliano RL. Motility of fibronectin receptor-deficient cells on fibronectin and vitronectin Collaborative interactions among integrins. J Cell Biol 1992; 116: 477-487
• 84 Blystone SD, Graham IL, Lindberg FP, Brown EJ. Integrin αvβ3 differentially regulates adhesive and phagocytic functions of the fibronectin receptor α5β1. J Cell Biol 1994; 127: 1129-1137
• 85 Meredith JE, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993; 4: 953-961
• 86 Re F, Zanetti A, Sironi M, Polentarutti N, Lanfrancone L, Dejana E, Colotta F. Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells. J Cell Biol 1994; 127: 537-546
• 87 Montgomery AM P, Reisfeld RA, Cheresh DA. Integrin αvβ3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 1994; 91: 8856-8860
• 88 Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresh DA. Involvement of integrin αv gene expression in human melanoma tumorigenicity. J Clin Invest 1992; 89: 2018-2022
• 89 Davis CM, Danehower SC, Laurenza A, Molony JL. Identification of a role of the vitronectin receptor and protein kinase C in the induction of endothelial cell vascular formation. J Cell Biol 1993; 51: 206-218
• 90 Brooks PC, Clark RA F, Cheresh DA. Requirement of vascular integrin ±v²3 for angiogenesis. Science 1994; 264: 569-571
• 91 Brooks PC, Montgomery AM. Rosenfeld M Reisfeld RA Hu T Klier G Cheresh DA Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-1164
• 92 Gamble JR, Matthias IJ, Meyer G, Kaur P, Russ G, Faull R, Berndt MC, Vadas MA. Regulation if in vitro capillary tube formation by anti-integrin antibodies. J Cell Biol 1993; 121: 931-943
• 93 Wagner EF, Risau W. Oncogenes in the study of endothelial cell growth and differentiation. Semin Cane Biol 1994; 5: 137-145
• 94 Savill J, Dransfield I, Hogg N, Haslett C. Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 1990; 343: 180-183
• 95 Parker CJ, Frame RN, Elstad MR. Vitronectin (S protein) augments the functional activity of monocyte receptors for IgG and complement C3b. Blood 1988; 71: 86-93
• 96 Leven RM, Tablin F. Extracellular matrix stimulation of guinea pig megakaryocyte proplatelet formation in vitro is mediated through the vitronectin receptor. Exp Hematol 1992; 20: 1316-1322
• 97 Zanetti A, Conforti G, Hess S, Martin-Padura I, Ghibaudi E, Preissner KT, Dejana E. Clustering of vitronectin and RGD peptides on microspheres leads to engagement of integrins on the luminal aspect of endothelial cell membrane. Blood. in press
• 98 Murphy JF, Bordet JC, Wyler B, Rissoan MC, Chomarat P, Defrance T, Miossec P, McGregor JL. The vitronectin receptor (αvβ3) is implicated in cooperation with P-selectin and plateletactivating-factor in the adhesion of monocytes to activated endothelial cells. Biochem J 1994; 304: 537-542
• 99 Panetti TS, McKeown-Longo PJ. The αvβ5 integrin receptor regulates receptor-mediated endocytosis of vitronectin. J Biol Chem 1993; 268: 11492-11495
• 100 Preissner KT, Anders E, Grulich-Henn J, Miiller-Berghaus G. Attachment of cultured human endothelial cells is promoted by specific association with S protein (vitronectin) as well as with the ternary S protein-thrombin-antithrombin III complex. Blood 1988; 71: 1581-1589
• 101 de Boer HC, Preissner KT, Bouma BN, de Groot PG. Binding of vitronectin-thrombin-antithrombin III complex to human endothelial cells is mediated by the heparin binding site of vitronectin. J Biol Chem 1992; 267: 2264-2268
• 102 Ciambrone GJ, McKeown-Longo PJ. Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells. J Biol Chem 1992; 267: 13617-13622
• 103 Pollanen J, Hedman K, Nielsen LS, Dano K, Vaheri A. Ultrastruc- tural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol 1988; 106: 87-95
• 104 Pollanen J, Saksela O, Salonen EM, Andreasen P, Nielsen L, Dano K, Vaheri A. Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol 1987; 104: 1085-1096
• 105 Pollanen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991; 57: 273-328
• 106 Orth K, Madison LE, Gething M, Sambrook JF, Herz J. Complexes of tissue-type plasminogen activator with PAI-1 are internalized by means of the low density lipoprotein receptor-related protein/α2-macroglobulin receptor. Proc Natl Acad Sci USA 1992; 89: 7422-7426
• 107 Bu G, Williams S, Strickland DK, Schwartz AL. Low density lipoprotein receptor related protein/a2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci USA 1992; 89: 7427-7431
• 108 Hoyer-Hansen G, Ronne E, Solberg H, Behrendt N, Ploug M, Lund LR, Ellis V, Dano K. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992; 267: 18224-18229
• 109 Gyetko MR, Todd III RF, Wilkinson CC, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 1994; 93: 1380-1387
• 110 Waltz DA, Sailor LZ, Chapman HA. Cytokines induce urokinase- dependent adhesion of human myeloid cells A regulatory role for plasminogen activator inhibitors. J Clin Invest 1993; 91: 1541-1552
• 111 Kook YH, Adamski J, Zelent A, Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 1994; 13: 3983-3991
• 112 Howell AL, Hunt JA, James TW, Mazar A, Henkin J, Zacharski LR. Urokinase inhibits HL-60 cell proliferation in vitro. Blood Coagul Fibrinol 1994; 5: 445-453
• 113 Waltz DA, Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 1994; 269: 14746-14750
• 114 Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-32388
• 115 Dumler I, Petri T, Schleuning WD. Interaction of urokinase-type plasminogen activator (u-PA) with its cellular receptor (u-PAR) induces phosphorylation on tyrosine of a 38 kDA protein. FEBS Lett 1993; 322: 37-40